Daewoong Co Ltd

Daewoong maintains a capital structure with a debt-to-equity ratio of 0.57, indicating moderate leverage. The company's liquidity position is characterized by a current ratio of 1.33, suggesting it can cover short-term obligations but with limited buffer. Free cash flow is negative at -64.17 billion KRW, and capital expenditures are substantial at -165.59 billion KRW, indicating ongoing investment in operations.

Profitability metrics show a return on equity (ROE) of 2.04% and a return on assets (ROA) of 0.78%, both below the typical thresholds for pharmaceutical firms. The gross margin is 54.4%, which is in line with industry norms, but the operating margin of 14.5% and net margin of 4.2% suggest pressure from cost structures and competitive pricing.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to domestic regulatory and market risks. No material revenue is attributed to international operations.

Outlook for the current fiscal year indicates a modest revenue growth trajectory, though specific numeric deltas are not provided. The company's operating cash flow of 54.33 billion KRW supports ongoing operations, but the negative free cash flow highlights the need for continued capital investment.

Risk factors include a medium liquidity risk due to negative net cash after subtracting total debt. The dilution risk is assessed as low, with no immediate pressure from share issuance or convertible instruments. The company's capital structure and cash flow dynamics suggest a cautious approach to financing.

Recent events include analyst price targets uniformly set at 28,000 KRW, indicating a consensus on the stock's fair value. The last actual EPS was 4,280 KRW, and the most recent revenue was 2.07 trillion KRW, aligning with the company's historical performance.

Daewoong Co Ltd (003090.KS) has been formally classified within the Healthcare economic sector, specifically under the Pharmaceuticals & Medical Research activity. This taxonomy update provides a clearer structural definition of the company’s operational focus, aligning its market identity with its core business functions in the health sciences domain. Alongside this sectoral clarification, the company’s risk profile has been updated with specific assessments for dilution and liquidity. Daewoong’s dilution risk is now rated as low, indicating a stable capital structure with minimal threat of share value erosion from new issuances. Conversely, liquidity risk has been assessed at a medium level, suggesting that while the company maintains operational fluidity, investors should monitor cash flow dynamics and market trading conditions more closely than in a low-risk scenario. These risk classifications offer a more granular view of the investment landscape for Daewoong. The combination of low dilution risk and medium liquidity risk implies that while shareholder equity is protected from aggressive expansion financing, the company’s ability to meet short-term obligations or navigate market volatility requires ongoing attention. This balanced risk profile is typical for specialized firms in the pharmaceutical research space, where capital intensity and regulatory timelines can influence cash requirements. The updated profile is supported by limited but specific market coverage, with one analyst currently tracking the company’s financials and estimates. Despite the absence of index membership or disclosed top holders in the current dataset, the formalization of its sector and risk metrics provides a foundational framework for evaluating Daewoong’s performance within the broader Healthcare industry. Investors can now contextualize the company’s financial data against sector-specific benchmarks for pharmaceutical and medical research entities.

Analysts project 72.1% upside to a consensus price target of 28,000 KRW from the current market price of 16,270 KRW.

Operating income is forecast to surge 29.0% year-over-year to 281.5 billion KRW in fiscal year 2026.

Net income is projected to grow at a 22.1% compound annual growth rate over the four-year period.

Cash conversion efficiency of 2.72 ranks as best-in-class compared to the pharmaceutical cohort median of 0.95.

Long-term debt is expected to nearly double to 878.2 billion KRW in fiscal year 2026, raising credit risk.

The company faces high credit risk and medium liquidity risk according to current risk flag assessments.

Capital expenditure intensity is in the bottom quartile of the cohort, suggesting heavy investment relative to revenue.

Revenue KRW 516.33B, +2,5% YoY; Operating income −44,8% YoY.

• ▍Revenue KRW 516.33B, +2,5% YoY
• ▍Operating income −44,8% YoY
• ▍Net income +352,6% YoY
• ▍Free cash flow +78,5% YoY
• ▍Net margin 13.5%

Revenue KRW 542.18B, +5,1% YoY; Operating income −20,8% YoY.

• ▍Revenue KRW 542.18B, +5,1% YoY
• ▍Operating income −20,8% YoY
• ▍Net income −9,8% YoY
• ▍Free cash flow −2 507,1% YoY
• ▍Net margin 7.4%

Revenue KRW 528.43B, +11,7% YoY; Operating income +24,2% YoY.

• ▍Revenue KRW 528.43B, +11,7% YoY
• ▍Operating income +24,2% YoY
• ▍Net income +94,6% YoY
• ▍Free cash flow +96,1% YoY
• ▍Net margin 7.4%

Revenue KRW 481.43B; Operating income KRW 61.14B.

• ▍Revenue KRW 481.43B
• ▍Operating income KRW 61.14B
• ▍Net margin 5.4%

Revenue KRW 503.89B; Operating income KRW 63.04B.

• ▍Revenue KRW 503.89B
• ▍Operating income KRW 63.04B
• ▍Net margin -5.5%

Revenue KRW 515.87B; Operating income KRW 101.71B.

• ▍Revenue KRW 515.87B
• ▍Operating income KRW 101.71B
• ▍Net margin 8.6%

Revenue KRW 473.29B; Operating income KRW 68.68B.

• ▍Revenue KRW 473.29B
• ▍Operating income KRW 68.68B
• ▍Net margin 4.2%

Revenue KRW 2.07T; Operating income KRW 281.52B.

• ▍Revenue KRW 2.07T
• ▍Operating income KRW 281.52B
• ▍Net margin 8.5%

Revenue KRW 1.81T, +6,9% YoY; Operating income +7,9% YoY.

• ▍Revenue KRW 1.81T, +6,9% YoY
• ▍Operating income +7,9% YoY
• ▍Net income +48,9% YoY
• ▍Free cash flow −84,5% YoY
• ▍Net margin 8.4%

Revenue KRW 1.70T, +12,3% YoY; Operating income +12,2% YoY.

• ▍Revenue KRW 1.70T, +12,3% YoY
• ▍Operating income +12,2% YoY
• ▍Net income +30,3% YoY
• ▍Free cash flow +62,9% YoY
• ▍Net margin 6.0%

Revenue KRW 1.51T; Operating income KRW 180.36B.

• ▍Revenue KRW 1.51T
• ▍Operating income KRW 180.36B
• ▍Net margin 5.2%